Should I Buy TDOC? TDOC 2026 Analysis

Should You Buy Teladoc Health Inc (TDOC) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

5.610

1 Day change

-2.26%

52 Week Range

15.210

Analysis Updated At

2026/01/26

Teladoc Health Inc (TDOC) is not a strong buy for a beginner, long-term investor with $50,000-$100,000 to invest. The stock faces stagnant revenue growth, declining paying members, and ongoing net losses. Technical indicators are bearish, and there are no significant positive catalysts to suggest a turnaround in the near term. While the company shows some improvement in net income and EPS, the overall financial performance and market sentiment remain weak.

Technical Analysis

The technical indicators for TDOC are bearish. The MACD is below 0 and negatively contracting, indicating a weak momentum. The RSI is neutral at 34.502, and the moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level of 6.136, with resistance levels at 7.469 and 7.881. The overall trend suggests limited upside potential in the short term.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

Faster international revenue growth and early signs of stabilization in U.S. cash-pay users for the BetterHelp platform. Analysts are cautiously optimistic about 2026, expecting normalized patterns where organic growth defines valuation.

Neutral/Negative Catalysts

Stagnant revenue growth, declining paying members for BetterHelp, ongoing net losses, and competitive challenges in international markets. Analysts have lowered price targets, and the stock has faced significant weakness disconnected from fundamentals. Gross margin dropped by 11.85% YoY, and the stock is underperforming in a challenging health tech sector.

Financial Performance

In Q3 2025, revenue dropped by 2.20% YoY to $626.4M. Net income improved to -$49.5M, up 48.78% YoY, and EPS increased to -$0.28, up 47.37% YoY. However, gross margin declined to 56.01%, down 11.85% YoY, reflecting cost pressures and operational inefficiencies.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts have mixed views on TDOC. Goldman Sachs and Citi have lowered price targets but maintain Buy and Neutral ratings, respectively. The consensus reflects cautious optimism for 2026, but the stock faces near-term challenges, including weaker consumer sentiment and macro uncertainties.

15 Analyst Rating

Wall Street analysts forecast TDOC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TDOC is 8.91 USD with a low forecast of 7.5 USD and a high forecast of 12 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

12 Hold

0 Sell

Hold

Current: 5.740

Low

7.5

Averages

8.91

High

Current: 5.740

Low

7.5

Averages

8.91

High

BofA

Allen Lutz

Neutral

downgrade

AI Analysis

2026-01-27

New

Reason

BofA

Allen Lutz

Price Target

AI Analysis

2026-01-27

New

downgrade

Neutral

Reason

BofA analyst Allen Lutz lowered the firm's price target on Teladoc to $7 from $7.50 and keeps a Neutral rating on the shares. Sensor Tower trends suggest Q4 revenue could be tracking in-line with consensus and slightly below the midpoint of Teladoc's guidance, states the analyst, whose lowered price target reflects lower peer multiples.

Goldman Sachs

Buy

downgrade

$9 -> $8

2026-01-16

Reason

Goldman Sachs

Price Target

$9 -> $8

2026-01-16

downgrade

Buy

Reason

Goldman Sachs lowered the firm's price target on Teladoc to $8 from $9 and keeps a Buy rating on the shares. MedTech and Healthcare IT stocks fell sharply from January 8-14, declining about 3% and 11%, respectively, in a move that appears largely disconnected from fundamentals, the analyst tells investors in a research note. Even companies pre-announcing above-consensus results saw share weakness, despite forward outlooks generally at or above current Street expectations, the firm says.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TDOC

Unlock Now

TDOC Should I Buy

TDOC Should I Buy

Should You Buy Teladoc Health Inc (TDOC) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch